Condition
Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
Total Trials
4
Recruiting
2
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results
Data Visualizations
Phase Distribution
4Total
P 2 (4)
Trial Status
Active Not Recruiting2
Recruiting2
Clinical Trials (4)
Showing 4 of 4 trials
NCT05507541Phase 2Active Not Recruiting
TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06834373Phase 2Recruiting
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
NCT05821088Phase 2Recruiting
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
NCT03038672Phase 2Active Not Recruiting
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
Showing all 4 trials